518 Higgs P et al. 47. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology. 2006;130(6):1607- 16. 48. Ohnishi K, Matsuo S, Matsutani K, Itahashi M, Kakihara K, Suzuki K, et al. Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol. 1996;91(7):1374-9. 49. Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend. 2010;110(1-2):167-71. 50. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology. 2002;36(5 Suppl 1):S210-9. 51. John-Baptiste A, Varenbut M, Lingley M, Nedd-Roderique T, Teplin D, Tomlinson G, et al. Treatment of hepatitis C infection for current or former substance abusers in a community setting. J Viral Hepat. 2009;16(8):557-67. 52. Seal KH, Currie SL, Shen H, Anand BS, Bini EJ, Brau N, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? J Clin Gastroenterol. 2007;41(2):199- 205. 53. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485- 92. 54. Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD. Hepatitis C Treatment for People With Severe Mental Illness. Psychosomatics. 2006;47(2):93-107. 55. Guadagnino V, Trotta MP, Carioti J, Caroleo B, Antinori A. Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Dig Liver Dis. 2006;38(2):119-24. 56. Hauser P, Morasco BJ, Linke A, Bjornson D, Ruimy S, Matthews A, et al. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics. 2009;50(5):500-5. 57. Reichenberg A, Gorman JM, Dieterich DT. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS. 2005;19(Suppl 3):S174-8. 58. Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with Intravenous drug users and hepatitis C treatment hepatitis C. Neurosci Lett. 2004;365(2):87-91. 59. Evon DM, Ramcharran D, Belle SH, Terrault NA, Fontana RJ, Fried MW. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol. 2009;104(12):2949-58. 60. Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull. 2010;36(1):165-72. 61. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet. 1999;354(9173):131-2. 62. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37(2):443-51. 63. Chainuvati S, Khalid SK, Kancir S, Shea M, Edwards J, Sernyak M, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. J Viral Hepat. 2006;13(4):235-41. 64. Ho SB, Nguyen H, Tetrick LL, Opitz GA, Basara ML, Dieperink E. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol. 2001;96(1):157-64. 65. Dell’Osso L, Pini S, Maggi L, Rucci P, Del Debbio A, Carlini M, et al. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. J Psychosom Res. 2007;62(3):349- 55. 66. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, et al. Depression during pegylated interferon- alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiat. 2005;66(1):41-8. 67. Fransen Van De Putte DE, Fischer K, Posthouwer D, Van Erpecum K, Mauser-Bunschoten EP. Occurrence, course and risk factors of depression during antiviral treatment for chronic hepatitis C in patients with inherited bleeding disorders: a prospective study. Haemophilia. 2009;15(2):544-51. 68. Huckans M, Mitchell A, Pavawalla S, Morasco BJ, Ruimy S, Loftis JM, et al. The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. Antiviral Therapy. 2010;15(1):111-9. 69. Schaefer M, Schwaiger M, Garkisch AS, Pich M, Hinzpeter A, Uebelhack R, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol. 2005;42(6):793-8. Hepat Mon. 2011;11(7):513-518